keyword
MENU ▼
Read by QxMD icon Read
search

pediatric crohns

keyword
https://www.readbyqxmd.com/read/29454792/clinical-and-genomic-correlates-of-neutrophil-reactive-oxygen-species-production-in-pediatric-patients-with-crohn-s-disease
#1
Lee A Denson, Ingrid Jurickova, Rebekah Karns, Kelly A Shaw, David J Cutler, David Okou, Anne Dodd, Kathryn Quinn, Kajari Mondal, Bruce J Aronow, Yael Haberman, Aaron Linn, Adam Price, Ramona Bezold, Kathleen Lake, Kimberly Jackson, Thomas D Walters, Anne Griffiths, Robert N Baldassano, Joshua D Noe, Jeffrey S Hyams, Wallace V Crandall, Barbara S Kirschner, Melvin B Heyman, Scott Snapper, Stephen L Guthery, Marla C Dubinsky, Neal S Leleiko, Anthony R Otley, Ramnik J Xavier, Christine Stevens, Mark J Daly, Michael E Zwick, Subra Kugathasan
BACKGROUND & AIMS: Individuals with monogenic disorders of phagocyte function develop chronic colitis that resembles Crohn's Disease (CD). We tested for associations between mutations in genes encoding NADPH oxidases, neutrophil function, and phenotypes of CD in pediatric patients. METHODS: We performed whole-exome sequence analysis to identify mutations in genes encoding NADPH oxidases (such as CYBA, CYBB, NCF1, NCF2, NCF4, RAC1, and RAC2) using DNA from 543 pediatric patients with inflammatory bowel diseases...
February 15, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29446858/enteral-nutrition-for-pediatric-crohn-s-disease-an-underutilized-therapy
#2
REVIEW
Ala K Shaikhkhalil, Wallace Crandall
Enteral nutrition (EN) for the treatment of Crohn's disease (CD) involves administration of a liquid nutrition product, administered orally or through tube feeding, while excluding typical dietary components. It is a safe and effective, but largely underused, therapy in the United States as a treatment for CD. EN is a particularly attractive option for pediatric CD as it avoids side effects of corticosteroids, improves growth, and may have a higher likelihood of achieving mucosal healing than some traditional medications...
February 15, 2018: Nutrition in Clinical Practice
https://www.readbyqxmd.com/read/29420227/azithromycin-and-metronidazole-versus-metronidazole-based-therapy-for-the-induction-of-remission-in-mild-to-moderate-paediatric-crohn-s-disease-a-randomised-controlled-trial
#3
Arie Levine, Michal Kori, Jarek Kierkus, Rotem Sigall Boneh, Malgorzata Sladek, Johanna C Escher, Eytan Wine, Baruch Yerushalmi, Jorge Amil Dias, Ron Shaoul, Gigi Veereman Wauters, Mona Boaz, Guila Abitbol, Athos Bousvaros, Dan Turner
OBJECTIVE: Crohn's disease (CD) pathogenesis associated with dysbiosis and presence of pathobionts in the lumen, intracellular compartments and epithelial biofilms. Azithromycin is active in all three compartments. Our goal was to evaluate if azithromycin-based therapy can improve response and induce remission compared with metronidazole alone in paediatric CD. DESIGN: This blinded randomised controlled trial allocated children 5-18 years with 10<Pediatric Crohn's Disease Activity Index (PCDAI)≤40 to azithromycin 7...
February 2, 2018: Gut
https://www.readbyqxmd.com/read/29417077/ciprofloxacin-use-in-hospitalized-children-approved-or-off-label
#4
Toktam Faghihi, Leila Yavari Tekmehdash, Mania Radfar, Kheirollah Gholami
Objective: Fluoroquinolones are not routinely used as the first-line antimicrobial therapy in pediatrics. The American Academy of Pediatrics (AAP) and the United States Food and Drug Administration (FDA) approved fluoroquinolones on certain indications in children. The aim of this study was to evaluate to what extent and how ciprofloxacin is used on approved indication or as off-label. Besides, dose adequacy and treatment duration were assessed. Methods: In a 10-month observational study, all children receiving systemic ciprofloxacin were assessed...
October 2017: Journal of Research in Pharmacy Practice
https://www.readbyqxmd.com/read/29397417/pediatric-crohn-disease-is-characterized-by-th1-in-the-terminal-ileum-and-th1-th17-immune-response-in-the-colon
#5
Ana Savić Mlakar, Iva Hojsak, Mladen Jergović, Samir Čimić, Krešo Bendelja
The aim of this study was to assess the expression of inflammatory mediators in the affected terminal ileum and colon in pediatric Crohn disease (CD) patients with different stages of disease. Additionally, we assessed the role of efflux transporters in disease pathogenesis and their correlation with immune response. The study included 26 CD patients (10 newly diagnosed (CD-new), 8 CD-treated, and 8 CD-remission) and 15 control subjects. The terminal ileum IFN-γ, IL-6, and IL-1β were elevated in CD-new, while in the colon, the IFN-γ, IL-17A, and IL-6 were elevated in both CD-new and CD-treated subgroups...
February 3, 2018: European Journal of Pediatrics
https://www.readbyqxmd.com/read/29397324/histologic-features-in-pediatric-ileitis-is-it-possible-to-tip-the-balance-towards-crohn-s-disease
#6
EDITORIAL
Salvatore Oliva, Gabrio Bassotti, Vincenzo Villanacci
No abstract text is available yet for this article.
January 1, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29391593/vitamin-d-status-and-risk-for-sarcopenia-in-youth-with-inflammatory-bowel-diseases
#7
D R Mager, M W Carroll, E Wine, K Siminoski, K MacDonald, C L Kluthe, P Medvedev, M Chen, J Wu, J M Turner, H Q Huynh
Suboptimal vitamin D (vitD) status and reduced lean body mass are highly prevalent in pediatric inflammatory bowel diseases (IBD). The study objective was to determine sarcopenia prevalence and associations with vitD status in newly diagnosed pediatric IBD. Children with Crohn's disease (CD; n = 58) and ulcerative colitis (UC; n = 27) were included. Primary outcomes included body composition (total/regional/percent fat mass (FM), fat-free mass (FFM), skeletal muscle mass (SMM)), and vitD status (serum 25(OH)D)...
February 1, 2018: European Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/29383303/higher-morbidity-of-monogenic-inflammatory-bowel-disease-compared-to-the-adolescent-onset-inflammatory-bowel-disease
#8
Kwang Yeon Kim, Eun Joo Lee, Ju Whi Kim, Jin Soo Moon, Ju Young Jang, Hye Ran Yang, Jae Sung Ko
Purpose: Monogenic inflammatory bowel disease (IBD) patients do not respond to conventional therapy and are associated with a higher morbidity. We summarized the clinical characteristics of monogenic IBD patients and compared their clinical outcomes to that of non-monogenic IBD patients. Methods: We performed a retrospective cohort study of all children <18 years old who were diagnosed with IBD between 2005 and 2016. A total of 230 children were enrolled. Monogenic IBD was defined as a presentation age less than 6 years old with confirmation of a genetic disorder...
January 2018: Pediatric Gastroenterology, Hepatology & Nutrition
https://www.readbyqxmd.com/read/29383299/early-biologic-treatment-in-pediatric-crohn-s-disease-catching-the-therapeutic-window-of-opportunity-in-early-disease-by-treat-to-target
#9
REVIEW
Ben Kang, Yon Ho Choe
The emergence of mucosal healing as a treatment goal that could modify the natural course of Crohn's disease and the accumulating evidence showing that biologics are most effective in achieving mucosal healing, along with the success of early treatment regimens for rheumatoid arthritis, have led to the identification of early Crohn's disease and development of the concept of catching the therapeutic window during the early disease course. Thus, an increasing number of pediatric gastroenterologists are adopting an early biologic treatment strategy with or without an immunomodulator...
January 2018: Pediatric Gastroenterology, Hepatology & Nutrition
https://www.readbyqxmd.com/read/29370898/postoperative-complications-of-pediatric-patients-with-inflammatory-bowel-disease-treated-with-vedolizumab
#10
Lori A Zimmerman, Jill M Zalieckas, Robert C Shamberger, Athos Bousvaros
BACKGROUND: Vedolizumab is a biologic, which inhibits leukocyte adhesion in the gut and is used to treat ulcerative colitis (UC) and Crohn's disease (CD). Little is known of the surgical outcomes in patients treated with vedolizumab. We reviewed the postoperative complications in a cohort of pediatric UC and CD patients treated with vedolizumab. METHODS: We identified pediatric UC and CD patients treated with vedolizumab at our institution from 2014 to 2016. We compared postoperative outcomes in the vedolizumab exposed group to a cohort of vedolizumab naïve patients who required diverting ileostomy...
December 16, 2017: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29361094/a-mobile-infliximab-dosing-calculator-for-therapy-optimization-in-inflammatory-bowel-disease
#11
Travis Piester, Adam Frymoyer, Megan Christofferson, Helen Yu, Dorsey Bass, K T Park
Background: Inadequate infliximab (IFX) drug exposure remains a clinical challenge and leads to high loss of response rates and therapy failure in inflammatory bowel disease (IBD). We aimed to determine the feasibility and pilot effectiveness of a novel, web-based, mobile IFX dosing calculator (mIDC) for therapy optimization. Methods: We developed an mIDC leveraging the known clinical variables of C-reative protein (CRP), albumin, patient's weight, disease activity indices, calprotectin, drug trough levels, and antibodies to IFX that significantly affect pharmacokinetics and/or outcomes...
January 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29361092/safety-clinical-response-and-microbiome-findings-following-fecal-microbiota-transplant-in-children-with-inflammatory-bowel-disease
#12
Alka Goyal, Andrew Yeh, Brian R Bush, Brian A Firek, Leah M Siebold, Matthew Brian Rogers, Adam D Kufen, Michael J Morowitz
Background: The role of fecal microbiota transplant (FMT) in the treatment of pediatric inflammatory bowel disease (IBD) is unknown. The aims of this study were to assess safety, clinical response, and gut microbiome alterations in children with Crohn's disease (CD), ulcerative colitis (UC), or indeterminate colitis (IC). Methods: In this open-label, single-center prospective trial, patients with IBD refractory to medical therapy underwent a single FMT by upper and lower endoscopy...
January 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29361088/long-ncrna-landscape-in-the-ileum-of-treatment-naive-early-onset-crohn-disease
#13
Yael Haberman, Marina BenShoshan, Ayelet Di Segni, Phillip J Dexheimer, Tzipi Braun, Batia Weiss, Thomas D Walters, Robert N Baldassano, Joshua D Noe, James Markowitz, Joel Rosh, Melvin B Heyman, Anne M Griffiths, Wallace V Crandall, David R Mack, Susan S Baker, Richard Kellermayer, Ashish Patel, Anthony Otley, Steven J Steiner, Ajay S Gulati, Stephen L Guthery, Neal LeLeiko, Dedrick Moulton, Barbara S Kirschner, Scott Snapper, Camila Avivi, Iris Barshack, Maria Oliva-Hemker, Stanley A Cohen, David J Keljo, David Ziring, Yair Anikster, Bruce Aronow, Jeffrey S Hyams, Subra Kugathasan, Lee A Denson
Background: Long noncoding RNAs (lncRNA) are key regulators of gene transcription and many show tissue-specific expression. We previously defined a novel inflammatory and metabolic ileal gene signature in treatment-naive pediatric Crohn disease (CD). We now extend our analyses to include potential regulatory lncRNA. Methods: Using RNAseq, we systematically profiled lncRNAs and protein-coding gene expression in 177 ileal biopsies. Co-expression analysis was used to identify functions and tissue-specific expression...
January 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29360691/age-at-disease-onset-of-inflammatory-bowel-disease-is-associated-with-later-extraintestinal-manifestations-and-complications
#14
Denise Herzog, Nicolas Fournier, Patrick Buehr, Vanessa Rueger, Rebekka Koller, Klaas Heyland, Andreas Nydegger, Johannes Spalinger, Susanne Schibli, Laetitia-Marie Petit, Christian P Braegger
INTRODUCTION: A small but increasing number of patients with inflammatory bowel disease are diagnosed during childhood or adolescence, and disease distribution and severity at onset vary according to the age at diagnosis. Clinical factors present at the time of diagnosis can be predictive of the disease course. AIM: The aim of this study was to characterize disease behavior and the cumulative complications and extraintestinal manifestations 10 years after the diagnosis and to assess their association with age at diagnosis...
January 22, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29360496/is-focal-active-colitis-of-greater-clinical-significance-in-pediatric-patients-a-retrospective-review-of-68-cases-with-clinical-correlation
#15
Allison Osmond, Dhandapani Ashok, Courtney A Francoeur, Michael Miller, Joanna C Walsh
Focal active colitis (FAC) is a histopathologic finding of uncertain clinical significance in individual patients. In adults, infection accounts for approximately 50%, Crohn's disease (CD) for 0-13%, and 20-30% are idiopathic. One previous study of 29 cases of pediatric FAC showed a 28% rate of CD. This study reviewed a larger cohort of pediatric patients to determine what proportion had IBD, and whether an amount or pattern of inflammation could predict IBD. Sixty eight patients aged ≤18years with FAC were identified and reviewed...
January 20, 2018: Human Pathology
https://www.readbyqxmd.com/read/29356768/real-life-anti-tumor-necrosis-factor-experience-in-more-than-500-patients-high-co-immunosuppression-rates-but-low-rates-of-quantifying-treatment-response
#16
Victoria M Merrick, Kajal Mortier, Linda J Williams, Rafeeq Muhammed, Marcus K H Auth, Mamoun Elawad, John M E Fell, R Mark Beattie, Sabarinathan Loganathan, Franco Torrente, Mary-Anne Morris, Charles Charlton, Nick M Croft, Astor Rodrigues, Mark Furman, Babu Vadamalayan, Huw Jenkins, Veena Zamvar, Sally G Mitton, Sonny Chong, Mike Cosgrove, Anthony Akobeng, David C Wilson, Richard K Russell
OBJECTIVE: The aim of this study was to measure the effectiveness, safety, and use of anti-tumor necrosis Factor (TNF) therapy in pediatric inflammatory bowel disease in the United Kingdom (UK). METHODS: Prospective UK audit of patients newly starting anti-TNF therapy. Disease severity was assessed using Physician Global Assessment +/or the Paediatric Crohn Disease Activity Index. RESULTS: A total of 37 centers participated (23/25 specialist pediatric inflammatory bowel disease sites)...
February 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29342997/-x-linked-inhibitor-of-apoptosis-deficiency-manifested-as-crohn-s-disease-a-case-report-and-literature-review
#17
L J Xu, Y Y Luo, J D Yu, J G Lou, Y H Fang, J Chen
Objective: To analyze the clinical characteristics of X-linked inhibitor of apoptosis (XIAP) deficient patients with clinical manifestation of Crohn's disease. Methods: Clinical manifestations, laboratory investigations, genetic testing and therapeutic interventions of one case of XIAP deficiency who was admitted to Department of Gastroenterology in Children's Hospital, Zhejiang University School of Medicine in May 2016 were summarized. PubMed and Chinese database for articles published from January 2016 to June 2017 were searched using the key words of'Crohn's disease'and'XIAP', and the relevant literature was reviewed...
January 2, 2018: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/29338679/therapeutic-role-of-methotrexate-in-pediatric-crohn-s-disease
#18
REVIEW
Zlatko Djurić, Ljiljana Šaranac, Ivana Budić, Voja Pavlović, Jelena Djordjević
The main role of therapy in Crohn's disease is to achieve long-term clinical remission, and to allow for normal growth and development of children. The immunomodulatory drugs used for the maintenance of remission in Crohn's disease include thiopurines (azathioprine and 6-mercaptopurine) and methotrexate. Development of hepatosplenic T-cell lymphoma in some patients with inflammatory bowel disease, treated with thiopurines independently or in combination with anti-tumor necrosis factor agents, resulted in a growing interest in the therapeutic application of methotrexate in children suffering from Crohn's disease...
January 16, 2018: Bosnian Journal of Basic Medical Sciences
https://www.readbyqxmd.com/read/29335008/multi-omics-differentially-classify-disease-state-and-treatment-outcome-in-pediatric-crohn-s-disease
#19
Gavin M Douglas, Richard Hansen, Casey M A Jones, Katherine A Dunn, André M Comeau, Joseph P Bielawski, Rachel Tayler, Emad M El-Omar, Richard K Russell, Georgina L Hold, Morgan G I Langille, Johan Van Limbergen
BACKGROUND: Crohn's disease (CD) has an unclear etiology, but there is growing evidence of a direct link with a dysbiotic microbiome. Many gut microbes have previously been associated with CD, but these have mainly been confounded with patients' ongoing treatments. Additionally, most analyses of CD patients' microbiomes have focused on microbes in stool samples, which yield different insights than profiling biopsy samples. RESULTS: We sequenced the 16S rRNA gene (16S) and carried out shotgun metagenomics (MGS) from the intestinal biopsies of 20 treatment-naïve CD and 20 control pediatric patients...
January 15, 2018: Microbiome
https://www.readbyqxmd.com/read/29330783/clinical-pharmacokinetics-and-pharmacodynamics-of-infliximab-in-the-treatment-of-inflammatory-bowel-disease
#20
REVIEW
Amy Hemperly, Niels Vande Casteele
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). It has been shown to induce and maintain both clinical remission and mucosal healing in pediatric and adult patients with inflammatory bowel disease (IBD) who are unresponsive or refractory to conventional therapies. The administration of infliximab is weight-based and the drug is administered intravenously. The volume of distribution of infliximab is low and at steady state ranges from 4...
January 12, 2018: Clinical Pharmacokinetics
keyword
keyword
68453
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"